董事介绍
注：董事持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Harrison M. Bains, Jr. | 男 | Director | 73 | 10.01万美元 | 未持股 | 2017-05-10 |
| Jeffrey L. Ives | 男 | Director | 66 | 9.76万美元 | 未持股 | 2017-05-10 |
| Derek Chalmers | -- | Director,President and Chief Executive Officer | 53 | 146.02万美元 | 未持股 | 2017-05-10 |
| Dean Slagel | 男 | Director | 47 | 8.51万美元 | 未持股 | 2017-05-10 |
| Martin Vogelbaum | 男 | Director | 53 | 13.26万美元 | 未持股 | 2017-05-10 |
高管介绍
注：高管持股数取自最新公司公告
| 姓名 | 性别 | 职位 | 年龄 | 薪酬 | 持股数(万股) | 截止日期 |
|---|---|---|---|---|---|---|
| Scott M. Terrillion | 男 | General Counsel, Secretary | 54 | 未披露 | 未持股 | 2017-05-10 |
| Joseph Stauffer | 男 | Chief Medical Officer | 51 | 89.64万美元 | 未持股 | 2017-05-10 |
| Derek Chalmers | -- | Director,President and Chief Executive Officer | 53 | 146.02万美元 | 未持股 | 2017-05-10 |
| Josef Schoell | 男 | Treasurer, Chief Financial Officer | 67 | 62.38万美元 | 未持股 | 2017-05-10 |
| Frederique Menzaghi | 女 | Vice President - Research and Development | 50 | 78.05万美元 | 未持股 | 2017-05-10 |
| Michael E. Lewis | 男 | Chief Scientific Advisor | 65 | 未披露 | 未持股 | 2017-05-10 |
董事简历
中英对照 | 中文 | 英文- Harrison M. Bains, Jr.
-
Harrison M. Bains, Jr.，2014年7月起，担任本公司董事。1988年直到2004年退休，他在Bristol Myers Squibb Company担任过许多职务，包括副总裁、财务总管、代理首席财务官。他还曾在Chase Manhattan Bank担任过基础行业部高级副总裁，并在 RJR Nabisco及其2个前身公司担任过高级副总裁、财务总管。目前，他是BG Medicine, Inc.的董事；注册投资公司Mercer Funds, Inc.的董事、前董事长；Bank of America Funds的董事。他从2007年10月起，担任Park Avenue Armory的董事；2007年9月起，担任Civil War Trust的董事；此前，1989年10月至2013年5月，担任University of Redlands的董事。他在University of California, Berkeley获得工商管理硕士学位，在University of Redlands获得经济学士学位，还在Harvard Business School完成了Advanced Management Program课程。
Harrison M. Bains, Jr. Mr. Bains, 73 has served as a member of our Board of Directors since July 2014. Mr. Bains served in multiple roles at Bristol Myers Squibb Company, including Vice President, Treasurer and acting Chief Financial Officer from 1988 through his retirement in 2004. Mr. Bains’s career also includes serving as Senior Vice President of the Primary Industries group at Chase Manhattan Bank and 11 years with RJR Nabisco and two of its predecessor companies as Senior Vice President and Treasurer. He currently serves as a director and chairman of the Mercer Funds, Inc., a registered investment company. He has served as a member of the board of trustees of the Park Avenue Armory since October 2007 and the Civil War Trust since September 2007 and previously served as a member of the board of trustees of the University of Redlands from October 1989 to May 2013 as a member of the board of directors of BG Medicine, Inc. from 2007 to 2015 and as a member of the Board of Directors of Bank of America Funds from 2010 to 2016. Mr. Bains earned an M.B.A from the University of California, Berkeley and a B.A. in economics from the University of Redlands. He also completed the Advanced Management Program at Harvard Business School. - Harrison M. Bains, Jr.，2014年7月起，担任本公司董事。1988年直到2004年退休，他在Bristol Myers Squibb Company担任过许多职务，包括副总裁、财务总管、代理首席财务官。他还曾在Chase Manhattan Bank担任过基础行业部高级副总裁，并在 RJR Nabisco及其2个前身公司担任过高级副总裁、财务总管。目前，他是BG Medicine, Inc.的董事；注册投资公司Mercer Funds, Inc.的董事、前董事长；Bank of America Funds的董事。他从2007年10月起，担任Park Avenue Armory的董事；2007年9月起，担任Civil War Trust的董事；此前，1989年10月至2013年5月，担任University of Redlands的董事。他在University of California, Berkeley获得工商管理硕士学位，在University of Redlands获得经济学士学位，还在Harvard Business School完成了Advanced Management Program课程。
- Harrison M. Bains, Jr. Mr. Bains, 73 has served as a member of our Board of Directors since July 2014. Mr. Bains served in multiple roles at Bristol Myers Squibb Company, including Vice President, Treasurer and acting Chief Financial Officer from 1988 through his retirement in 2004. Mr. Bains’s career also includes serving as Senior Vice President of the Primary Industries group at Chase Manhattan Bank and 11 years with RJR Nabisco and two of its predecessor companies as Senior Vice President and Treasurer. He currently serves as a director and chairman of the Mercer Funds, Inc., a registered investment company. He has served as a member of the board of trustees of the Park Avenue Armory since October 2007 and the Civil War Trust since September 2007 and previously served as a member of the board of trustees of the University of Redlands from October 1989 to May 2013 as a member of the board of directors of BG Medicine, Inc. from 2007 to 2015 and as a member of the Board of Directors of Bank of America Funds from 2010 to 2016. Mr. Bains earned an M.B.A from the University of California, Berkeley and a B.A. in economics from the University of Redlands. He also completed the Advanced Management Program at Harvard Business School.
- Jeffrey L. Ives
-
Jeffrey L. Ives，自2014年7月接受本公司董事会任命填补空缺之时起，一直担任董事。2008-2013，他担任Satori Pharmaceuticals, Inc.的首席执行官，这是一个神经退行性疾病公司，专注于Alzheimer治疗和预防的突破性疗法的研究和开发。此前，他在Pfizer领导CNS、疼痛、肿瘤研究团队长达20多年；2001-2007，担任高级副总裁，领导全球药代动力学、动力学、新陈代谢相关部门。他在Yale University获得博士、硕士学位，在Colgate University获得学士学位。
Jeffrey L. Ives has served as a member of our board of directors since May 2014. Dr. Ives has served as a director on the board of Cara Therapeutics since 2014. He currently also serves on the boards of several neurodegenerative disease companies including Pinteon Therapeutics, Orthogonal Neuroscience, and Astrocyte Pharmaceuticals. From 2008 until 2013 Dr. Ives served as the Chief Executive Officer of Satori Pharmaceuticals, Inc., a company focused on Alzheimer’s disease. Prior to Satori, he served as senior vice president at Pfizer, leading the neurodegenerative diseases, psychiatry and pain research areas. Dr. Ives received his doctorate and master’s degrees from Yale University and received his B.A. from Colgate University. - Jeffrey L. Ives，自2014年7月接受本公司董事会任命填补空缺之时起，一直担任董事。2008-2013，他担任Satori Pharmaceuticals, Inc.的首席执行官，这是一个神经退行性疾病公司，专注于Alzheimer治疗和预防的突破性疗法的研究和开发。此前，他在Pfizer领导CNS、疼痛、肿瘤研究团队长达20多年；2001-2007，担任高级副总裁，领导全球药代动力学、动力学、新陈代谢相关部门。他在Yale University获得博士、硕士学位，在Colgate University获得学士学位。
- Jeffrey L. Ives has served as a member of our board of directors since May 2014. Dr. Ives has served as a director on the board of Cara Therapeutics since 2014. He currently also serves on the boards of several neurodegenerative disease companies including Pinteon Therapeutics, Orthogonal Neuroscience, and Astrocyte Pharmaceuticals. From 2008 until 2013 Dr. Ives served as the Chief Executive Officer of Satori Pharmaceuticals, Inc., a company focused on Alzheimer’s disease. Prior to Satori, he served as senior vice president at Pfizer, leading the neurodegenerative diseases, psychiatry and pain research areas. Dr. Ives received his doctorate and master’s degrees from Yale University and received his B.A. from Colgate University.
- Derek Chalmers
-
Derek Chalmers是公司的创始人之一，自2004年9月起一直担任我们的总裁和首席执行官，并在自2004年6月起一直是我们董事会的一名成员。Chalmers博士在生物科技行业公司任职有超过19年的经历。在城里我们公司之前，Chakmers小博士共同成立了Arena Pharmaceuticals（一家药物研发公司），并在1997年6月到2004年5月期间担任了副总裁和执行董事。Chalmers博士拥有University of Glasgow的理学士学位和药理学博士学位。
Derek Chalmers, Ph.D., D.Sc. Dr. Chalmers, 53 one of our founders, has served as our President and Chief Executive Officer since September 2004 and has served as a member of our Board of Directors since July 2004. Dr. Chalmers has over 22 years’ experience in the biotechnology industry with increasing levels of corporate and business responsibilities. Prior to founding our company, Dr. Chalmers co-founded Arena Pharmaceuticals, Inc. NASDAQ: ARNA, a drug discovery and development company, and served as its Vice President and Executive Director from June 1997 until May 2004. Prior to Arena, Dr. Chalmers was a Group Leader at Neurocrine Biosciences (NASDAQ: NBIX). Dr. Chalmers holds a D.Sc. and Ph.D. in Pharmacology from the University of Glasgow. - Derek Chalmers是公司的创始人之一，自2004年9月起一直担任我们的总裁和首席执行官，并在自2004年6月起一直是我们董事会的一名成员。Chalmers博士在生物科技行业公司任职有超过19年的经历。在城里我们公司之前，Chakmers小博士共同成立了Arena Pharmaceuticals（一家药物研发公司），并在1997年6月到2004年5月期间担任了副总裁和执行董事。Chalmers博士拥有University of Glasgow的理学士学位和药理学博士学位。
- Derek Chalmers, Ph.D., D.Sc. Dr. Chalmers, 53 one of our founders, has served as our President and Chief Executive Officer since September 2004 and has served as a member of our Board of Directors since July 2004. Dr. Chalmers has over 22 years’ experience in the biotechnology industry with increasing levels of corporate and business responsibilities. Prior to founding our company, Dr. Chalmers co-founded Arena Pharmaceuticals, Inc. NASDAQ: ARNA, a drug discovery and development company, and served as its Vice President and Executive Director from June 1997 until May 2004. Prior to Arena, Dr. Chalmers was a Group Leader at Neurocrine Biosciences (NASDAQ: NBIX). Dr. Chalmers holds a D.Sc. and Ph.D. in Pharmacology from the University of Glasgow.
- Dean Slagel
-
Dean Slagel自2005年2月起一直担任我们公司董事会的成员。Slagel先生是 Esperante BV和Esperante AB（两家分别在2004年9月和2005年6月成立的生物科学风险投资公司）的总经理。1995年9月到2004年9月期间，Slagel先生在Ferring Pharmaceuticals（一家主要基于英国，法国和丹麦的专业的生物制药集团）的国际业务发展部担任主管。他在2000年获得了法国巴黎ENPC Business School的工商管理硕士学位。
Dean Slagel. Mr. Slagel, 47 has served as a member of our Board of Directors since February 2005. Mr. Slagel is the Managing Director of Esperante BV and Esperante AB, life sciences venture investment companies founded in September 2004 and June 2005 respectively. From September 1995 to September 2004 Mr. Slagel served as the Global Business Development Director of Ferring Pharmaceuticals, a specialty biopharmaceutical group then based principally in the UK, France and Denmark. He received an M.B.A. from the ENPC Business School in Paris, France, in 2000. - Dean Slagel自2005年2月起一直担任我们公司董事会的成员。Slagel先生是 Esperante BV和Esperante AB（两家分别在2004年9月和2005年6月成立的生物科学风险投资公司）的总经理。1995年9月到2004年9月期间，Slagel先生在Ferring Pharmaceuticals（一家主要基于英国，法国和丹麦的专业的生物制药集团）的国际业务发展部担任主管。他在2000年获得了法国巴黎ENPC Business School的工商管理硕士学位。
- Dean Slagel. Mr. Slagel, 47 has served as a member of our Board of Directors since February 2005. Mr. Slagel is the Managing Director of Esperante BV and Esperante AB, life sciences venture investment companies founded in September 2004 and June 2005 respectively. From September 1995 to September 2004 Mr. Slagel served as the Global Business Development Director of Ferring Pharmaceuticals, a specialty biopharmaceutical group then based principally in the UK, France and Denmark. He received an M.B.A. from the ENPC Business School in Paris, France, in 2000.
- Martin Vogelbaum
-
Martin Vogelbaum自2010年7月起一直担任我们董事会的一名成员。Vogelbaum先生在2005年起一直担任Rho Ventures的合伙人，并主要从事于生物科技，生物制药和医疗设备行业的投资。他在生物科学行业投资有超过19年的经理，其中包括在各种不同发展水平的公司工作和是超过6个公司的联合创始人。Vogelbaum先生目前是Nephrogenex的一名董事。2007年到2010年期间，Vogelbaum先生曾担任 Middlebrook Pharmaceuticals的董事会成员。在他的风险资本职业生涯开始之前，他在 Memorial-Sloan Kettering医院的骨髓移植研究会成员，并在此进行移植物抗宿主病的研究。Vogelbaum先生在哥伦比亚大学获得了生物学和历史学博士学位。
Martin Vogelbaum. Mr. Vogelbaum, 53 has served as a member of our Board of Directors since July 2010. He is currently Corporate Vice President, Business Development at Celgene Corporation. Prior to joining Celgene, Mr. Vogelbaum served as a partner of Rho Ventures from 2005 until 2015 where he focused on investments in biotechnology, biopharmaceuticals and medical devices. He has more than 22 years of experience investing in the life sciences sector, having been involved with companies at all stages of development, including co-founding more than a half dozen companies. Prior to his venture capital career, he was a research associate in the bone marrow transplantation unit at Memorial-Sloan Kettering Hospital, where he conducted research in graft-versus-host-disease GVHD. Mr. Vogelbaum previously served as a director of Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) from 2010 to 2016 and NephroGenex, Inc. (NASDAQ: NRX) from 2013 to 2014. He currently serves on the Healthcare Advisory Board for the Partnership Fund for New York City as well as the Scientific Advisory Committee for Weill Cornell Medical College’s Daedalus Fund for Innovation. Mr. Vogelbaum received his A.B. in biology and history from Columbia University. - Martin Vogelbaum自2010年7月起一直担任我们董事会的一名成员。Vogelbaum先生在2005年起一直担任Rho Ventures的合伙人，并主要从事于生物科技，生物制药和医疗设备行业的投资。他在生物科学行业投资有超过19年的经理，其中包括在各种不同发展水平的公司工作和是超过6个公司的联合创始人。Vogelbaum先生目前是Nephrogenex的一名董事。2007年到2010年期间，Vogelbaum先生曾担任 Middlebrook Pharmaceuticals的董事会成员。在他的风险资本职业生涯开始之前，他在 Memorial-Sloan Kettering医院的骨髓移植研究会成员，并在此进行移植物抗宿主病的研究。Vogelbaum先生在哥伦比亚大学获得了生物学和历史学博士学位。
- Martin Vogelbaum. Mr. Vogelbaum, 53 has served as a member of our Board of Directors since July 2010. He is currently Corporate Vice President, Business Development at Celgene Corporation. Prior to joining Celgene, Mr. Vogelbaum served as a partner of Rho Ventures from 2005 until 2015 where he focused on investments in biotechnology, biopharmaceuticals and medical devices. He has more than 22 years of experience investing in the life sciences sector, having been involved with companies at all stages of development, including co-founding more than a half dozen companies. Prior to his venture capital career, he was a research associate in the bone marrow transplantation unit at Memorial-Sloan Kettering Hospital, where he conducted research in graft-versus-host-disease GVHD. Mr. Vogelbaum previously served as a director of Inotek Pharmaceuticals Corporation (NASDAQ: ITEK) from 2010 to 2016 and NephroGenex, Inc. (NASDAQ: NRX) from 2013 to 2014. He currently serves on the Healthcare Advisory Board for the Partnership Fund for New York City as well as the Scientific Advisory Committee for Weill Cornell Medical College’s Daedalus Fund for Innovation. Mr. Vogelbaum received his A.B. in biology and history from Columbia University.
高管简历
中英对照 | 中文 | 英文- Scott M. Terrillion
这是ScottM.TerrillionTerrilon先生于2016年11月加入Cara Therapeutics，担任我们的总法律顾问。Terrilon先生监管Cara’；的法律和合规职能，并担任公司秘书。2014年9月至2016年10月，Terrillion先生担任Mesoblast，Inc.（一家公开上市的新兴生物技术公司）的Vice President，副总法律顾问兼合规主管。在加入Mesoblast之前，Terrillion先生曾在勃林格殷格翰制药公司（Boehringer Ingelheim Pharmaceuticals，Inc.）工作，1998年6月至2014年9月，他担任该公司的Vice President兼副总法律顾问。Terrion先生在Nixon，Hargrave，Devans&Doyle开始了他的法律职业生涯，现在是Nixon Peabody，一家大型的全科律师事务所，在那里他是医疗保健和技术/知识产权实践集团的合伙人。Terrilon先生作为社区药剂师开始了他的职业生涯，后来担任Preferred Care，Inc.的药剂部总监，这是一家HMO保险提供商。Terrilon先生在奥尔巴尼药学和健康科学学院（Albany College of Pharmacy and Health Sciences）获得药学学士学位，在那里他担任董事会成员，并在奥尔巴尼法学院（Albany Law School）以优异成绩获得法学博士学位。他是the New York Bar的成员。
Scott M. Terrillion. Mr. Terrillion joined Cara Therapeutics in November 2016 as our General Counsel. Mr. Terrillion oversees Cara’s legal and compliance functions and serves as Company Secretary. From September 2014 to October 2016 Mr. Terrillion served as Vice President, Associate General Counsel and Head of Compliance at Mesoblast, Inc., a publicly traded emerging biotech. Prior to Mesoblast, Mr. Terrillion worked at Boehringer Ingelheim Pharmaceuticals, Inc., where he served as Vice President, Associate General Counsel from June 1998 to September 2014. Mr. Terrillion began his legal career at Nixon, Hargrave, Devans & Doyle now Nixon Peabody, a large general practice law firm, where he was an associate in the Health Care and Technology/Intellectual Property Practice groups. Mr. Terrillion began his professional career as a community pharmacist and later served as Director of Pharmacy for Preferred Care, Inc., a HMO insurance provider. Mr. Terrillion received his B.S. in Pharmacy from the Albany College of Pharmacy and Health Sciences, where he serves on the Board of Trustees, and a Juris Doctor, magna cum laude, from Albany Law School. He is a member of the New York bar.- 这是ScottM.TerrillionTerrilon先生于2016年11月加入Cara Therapeutics，担任我们的总法律顾问。Terrilon先生监管Cara’；的法律和合规职能，并担任公司秘书。2014年9月至2016年10月，Terrillion先生担任Mesoblast，Inc.（一家公开上市的新兴生物技术公司）的Vice President，副总法律顾问兼合规主管。在加入Mesoblast之前，Terrillion先生曾在勃林格殷格翰制药公司（Boehringer Ingelheim Pharmaceuticals，Inc.）工作，1998年6月至2014年9月，他担任该公司的Vice President兼副总法律顾问。Terrion先生在Nixon，Hargrave，Devans&Doyle开始了他的法律职业生涯，现在是Nixon Peabody，一家大型的全科律师事务所，在那里他是医疗保健和技术/知识产权实践集团的合伙人。Terrilon先生作为社区药剂师开始了他的职业生涯，后来担任Preferred Care，Inc.的药剂部总监，这是一家HMO保险提供商。Terrilon先生在奥尔巴尼药学和健康科学学院（Albany College of Pharmacy and Health Sciences）获得药学学士学位，在那里他担任董事会成员，并在奥尔巴尼法学院（Albany Law School）以优异成绩获得法学博士学位。他是the New York Bar的成员。
- Scott M. Terrillion. Mr. Terrillion joined Cara Therapeutics in November 2016 as our General Counsel. Mr. Terrillion oversees Cara’s legal and compliance functions and serves as Company Secretary. From September 2014 to October 2016 Mr. Terrillion served as Vice President, Associate General Counsel and Head of Compliance at Mesoblast, Inc., a publicly traded emerging biotech. Prior to Mesoblast, Mr. Terrillion worked at Boehringer Ingelheim Pharmaceuticals, Inc., where he served as Vice President, Associate General Counsel from June 1998 to September 2014. Mr. Terrillion began his legal career at Nixon, Hargrave, Devans & Doyle now Nixon Peabody, a large general practice law firm, where he was an associate in the Health Care and Technology/Intellectual Property Practice groups. Mr. Terrillion began his professional career as a community pharmacist and later served as Director of Pharmacy for Preferred Care, Inc., a HMO insurance provider. Mr. Terrillion received his B.S. in Pharmacy from the Albany College of Pharmacy and Health Sciences, where he serves on the Board of Trustees, and a Juris Doctor, magna cum laude, from Albany Law School. He is a member of the New York bar.
- Joseph Stauffer
Joseph Stauffer，工商管理硕士学位，2009年加入DURECT，担任首席医务官和公司战略执行副总裁。加入DURECT前，他2004至2009年在Alpharma Inc.工作，最近一职是担任首席医务官和临床研究和医疗事务部高级副总裁。加入Alpharma前，他2002至2004年在Abbott Laboratories工作，担任全球医务主管。此前，2000至2002年他在FDA工作，担任Drug Evaluation and Research的止痛剂部门的药品检验官。他是the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials （IMMPACT）的创始成员。这是制药厂、FDA、NIH、学术机构和专利小组联合机构，致力于帮助开发慢性病临床试验的核心领域和成果。他毕业于the Philadelphia College of Osteopathic Medicine，并在the Johns Hopkins University Hospital完成了麻醉科的住院实习，他现在是麻醉和关键护理药品部的兼职助理教授。他是美国海军退伍军人，退伍时担任中尉指挥官，此前担任8年海军医务官。他2009年9月，作为TRIUM Global的一部分，完成了其工商管理硕士学位。
Joseph Stauffer, D.O., MBA. Dr. Stauffer joined Cara Therapeutics on December 1 2014 and serves as our Chief Medical Officer. He has over 20 years of medical practice and clinical research experience. Prior to joining Cara, he served as Chief Medical Officer of both public and private biopharma and specialty pharma companies, including Alpharma Pharmaceuticals, Inc. from 2004 to 2009 Durect Corporation from 2009 to 2011 and Ikaria from 2012 to 2014. While at Alpharma Pharmaceuticals he led the design and execution of the clinical development program for EMBEDA, the first abuse-deterrent long-acting opioid analgesic approved by the FDA. Dr. Stauffer began his industry career as Global Medical Director at Abbott Laboratories. Prior to Abbott he worked at FDA as a Medical Review Officer in the Anti-Inflammatory & Analgesic Division of the Center for Drug Evaluation and Research. He completed his Anesthesiology residency at the Johns Hopkins University Hospital and served on both active duty and in active reserve roles as a physician medical officer in the United States Navy. He was honorably discharged as a Lt. Commander in 2001. He has served as an expert clinical research reviewer for the European Commission and maintains an appointment as Assistant Professor in the Department of Anesthesiology and Critical Care Medicine at the Johns Hopkins University School of Medicine. He received his M.B.A. from a joint program TRIUM between New York University, Stern School of Business, London School of Economics (LSE) and HEC (Hautes Etudes Commerciales) School of Management in Paris. He maintains an active medical license in the state of Pennsylvania.- Joseph Stauffer，工商管理硕士学位，2009年加入DURECT，担任首席医务官和公司战略执行副总裁。加入DURECT前，他2004至2009年在Alpharma Inc.工作，最近一职是担任首席医务官和临床研究和医疗事务部高级副总裁。加入Alpharma前，他2002至2004年在Abbott Laboratories工作，担任全球医务主管。此前，2000至2002年他在FDA工作，担任Drug Evaluation and Research的止痛剂部门的药品检验官。他是the Initiative on Methods, Measurement and Pain Assessment in Clinical Trials （IMMPACT）的创始成员。这是制药厂、FDA、NIH、学术机构和专利小组联合机构，致力于帮助开发慢性病临床试验的核心领域和成果。他毕业于the Philadelphia College of Osteopathic Medicine，并在the Johns Hopkins University Hospital完成了麻醉科的住院实习，他现在是麻醉和关键护理药品部的兼职助理教授。他是美国海军退伍军人，退伍时担任中尉指挥官，此前担任8年海军医务官。他2009年9月，作为TRIUM Global的一部分，完成了其工商管理硕士学位。
- Joseph Stauffer, D.O., MBA. Dr. Stauffer joined Cara Therapeutics on December 1 2014 and serves as our Chief Medical Officer. He has over 20 years of medical practice and clinical research experience. Prior to joining Cara, he served as Chief Medical Officer of both public and private biopharma and specialty pharma companies, including Alpharma Pharmaceuticals, Inc. from 2004 to 2009 Durect Corporation from 2009 to 2011 and Ikaria from 2012 to 2014. While at Alpharma Pharmaceuticals he led the design and execution of the clinical development program for EMBEDA, the first abuse-deterrent long-acting opioid analgesic approved by the FDA. Dr. Stauffer began his industry career as Global Medical Director at Abbott Laboratories. Prior to Abbott he worked at FDA as a Medical Review Officer in the Anti-Inflammatory & Analgesic Division of the Center for Drug Evaluation and Research. He completed his Anesthesiology residency at the Johns Hopkins University Hospital and served on both active duty and in active reserve roles as a physician medical officer in the United States Navy. He was honorably discharged as a Lt. Commander in 2001. He has served as an expert clinical research reviewer for the European Commission and maintains an appointment as Assistant Professor in the Department of Anesthesiology and Critical Care Medicine at the Johns Hopkins University School of Medicine. He received his M.B.A. from a joint program TRIUM between New York University, Stern School of Business, London School of Economics (LSE) and HEC (Hautes Etudes Commerciales) School of Management in Paris. He maintains an active medical license in the state of Pennsylvania.
- Derek Chalmers
Derek Chalmers是公司的创始人之一，自2004年9月起一直担任我们的总裁和首席执行官，并在自2004年6月起一直是我们董事会的一名成员。Chalmers博士在生物科技行业公司任职有超过19年的经历。在城里我们公司之前，Chakmers小博士共同成立了Arena Pharmaceuticals（一家药物研发公司），并在1997年6月到2004年5月期间担任了副总裁和执行董事。Chalmers博士拥有University of Glasgow的理学士学位和药理学博士学位。
Derek Chalmers, Ph.D., D.Sc. Dr. Chalmers, 53 one of our founders, has served as our President and Chief Executive Officer since September 2004 and has served as a member of our Board of Directors since July 2004. Dr. Chalmers has over 22 years’ experience in the biotechnology industry with increasing levels of corporate and business responsibilities. Prior to founding our company, Dr. Chalmers co-founded Arena Pharmaceuticals, Inc. NASDAQ: ARNA, a drug discovery and development company, and served as its Vice President and Executive Director from June 1997 until May 2004. Prior to Arena, Dr. Chalmers was a Group Leader at Neurocrine Biosciences (NASDAQ: NBIX). Dr. Chalmers holds a D.Sc. and Ph.D. in Pharmacology from the University of Glasgow.- Derek Chalmers是公司的创始人之一，自2004年9月起一直担任我们的总裁和首席执行官，并在自2004年6月起一直是我们董事会的一名成员。Chalmers博士在生物科技行业公司任职有超过19年的经历。在城里我们公司之前，Chakmers小博士共同成立了Arena Pharmaceuticals（一家药物研发公司），并在1997年6月到2004年5月期间担任了副总裁和执行董事。Chalmers博士拥有University of Glasgow的理学士学位和药理学博士学位。
- Derek Chalmers, Ph.D., D.Sc. Dr. Chalmers, 53 one of our founders, has served as our President and Chief Executive Officer since September 2004 and has served as a member of our Board of Directors since July 2004. Dr. Chalmers has over 22 years’ experience in the biotechnology industry with increasing levels of corporate and business responsibilities. Prior to founding our company, Dr. Chalmers co-founded Arena Pharmaceuticals, Inc. NASDAQ: ARNA, a drug discovery and development company, and served as its Vice President and Executive Director from June 1997 until May 2004. Prior to Arena, Dr. Chalmers was a Group Leader at Neurocrine Biosciences (NASDAQ: NBIX). Dr. Chalmers holds a D.Sc. and Ph.D. in Pharmacology from the University of Glasgow.
- Josef Schoell
Josef Schoell自2006年5月起一直担任我们公司的首席财务官。2005年5月，他加入我们公司，并在到2006年5月为止担任公司的主管。Schoell在财务和会计方面有超过20年的经历，其中包括在生物科技行业从事18年工作。2003年起到他2005年6月加入我们公司，Schoell先生曾是Robert Half Management Resources（一家会计和财务公司）担任一名顾问；1995年到2002年期间，他曾担任American Biogenetic Sciences（一家生物科技公司）的首席财务官和副总裁。Schoell先生获得了New York University Stern School商学院的会计学学士学位，并且现在是一名注册会计师。Schoell先生注册美国注册会计师和国际财务执行协会的一名成员。
Josef Schoell. Mr. Schoell has served as our Chief Financial Officer since May 2006. He joined us in May 2005 and served as our Controller between then and May 2006. Mr. Schoell has over 25 years of financial and accounting experience, including 20 years in the biotechnology industry. From 2003 until joining our company in May 2005 Mr. Schoell was a consultant with Robert Half Management Resources, a provider of accounting and financial professionals. From 1995 to 2002 he served as the Chief Financial Officer and Vice President - Finance, of American Biogenetic Sciences Inc., a biotechnology company. Mr. Schoell received a B.S. in Accounting from the New York University Stern School of Business and is a Certified Public Accountant. Mr. Schoell is a member of the American Institute of Certified Public Accountants and Financial Executives International.- Josef Schoell自2006年5月起一直担任我们公司的首席财务官。2005年5月，他加入我们公司，并在到2006年5月为止担任公司的主管。Schoell在财务和会计方面有超过20年的经历，其中包括在生物科技行业从事18年工作。2003年起到他2005年6月加入我们公司，Schoell先生曾是Robert Half Management Resources（一家会计和财务公司）担任一名顾问；1995年到2002年期间，他曾担任American Biogenetic Sciences（一家生物科技公司）的首席财务官和副总裁。Schoell先生获得了New York University Stern School商学院的会计学学士学位，并且现在是一名注册会计师。Schoell先生注册美国注册会计师和国际财务执行协会的一名成员。
- Josef Schoell. Mr. Schoell has served as our Chief Financial Officer since May 2006. He joined us in May 2005 and served as our Controller between then and May 2006. Mr. Schoell has over 25 years of financial and accounting experience, including 20 years in the biotechnology industry. From 2003 until joining our company in May 2005 Mr. Schoell was a consultant with Robert Half Management Resources, a provider of accounting and financial professionals. From 1995 to 2002 he served as the Chief Financial Officer and Vice President - Finance, of American Biogenetic Sciences Inc., a biotechnology company. Mr. Schoell received a B.S. in Accounting from the New York University Stern School of Business and is a Certified Public Accountant. Mr. Schoell is a member of the American Institute of Certified Public Accountants and Financial Executives International.
- Frederique Menzaghi
Frederique Menzaghi是我们公司的创始人之一，并在自2004年9月起一直担任我们公司的研发部副主管。Menzaghi博士在生物科技行业的药物研发和管理有超过20年的经历。1999年到2003年期间，Menzaghi博士曾担任 Arena Pharmaceuticals（纳斯达克：ARNA）的药理学研究主任，并在2003年到2004年期间担任Psychogenics（一家为中枢神经系统的临床前提供服务的公司）的药理学和业务发展部的副主管。Menzaghi博士获得了法国，斯特拉斯堡Louis Pasteur University的神经科学的博士学位和University of Nancy的临床心理科的硕士学位。
Frederique Menzaghi, Ph.D. Dr. Menzaghi, one of our founders, has served as our Vice President - Research and Development since September 2004 leading our preclinical research and pruritic clinical program. Dr. Menzaghi has over 25 years of drug development and management experiencein biotechnology. From 2003 to 2004 she served as Vice President, Pharmacology and Business Development at Psychogenics Inc., a preclinical contract research organization. From 1999 to 2003 Dr. Menzaghi was the Research Director of In Vivo Pharmacology at Arena Pharmaceuticals NASDAQ: ARNA leading a multidisciplinary research team. Prior to that, Dr. Menzaghi established and directed a preclinical research laboratory at SIBIA Neurosciences, Inc., a biotechnology firm. Her research expertise ranged from the development of small molecules to small peptides. Dr. Menzaghi received her Ph.D. in Neurosciences from the University of Louis Pasteur, Strasbourg, France and a M.Sc. in Clinical Psychology from the University of Nancy, France, after which she conducted her post-doctoral research at the Scripps Research Institute, San Diego, California. Dr. Menzaghi has over 55 peer-reviewed publications and book chapters, 100 international meeting presentations and is listed as an inventor on numerous patents.- Frederique Menzaghi是我们公司的创始人之一，并在自2004年9月起一直担任我们公司的研发部副主管。Menzaghi博士在生物科技行业的药物研发和管理有超过20年的经历。1999年到2003年期间，Menzaghi博士曾担任 Arena Pharmaceuticals（纳斯达克：ARNA）的药理学研究主任，并在2003年到2004年期间担任Psychogenics（一家为中枢神经系统的临床前提供服务的公司）的药理学和业务发展部的副主管。Menzaghi博士获得了法国，斯特拉斯堡Louis Pasteur University的神经科学的博士学位和University of Nancy的临床心理科的硕士学位。
- Frederique Menzaghi, Ph.D. Dr. Menzaghi, one of our founders, has served as our Vice President - Research and Development since September 2004 leading our preclinical research and pruritic clinical program. Dr. Menzaghi has over 25 years of drug development and management experiencein biotechnology. From 2003 to 2004 she served as Vice President, Pharmacology and Business Development at Psychogenics Inc., a preclinical contract research organization. From 1999 to 2003 Dr. Menzaghi was the Research Director of In Vivo Pharmacology at Arena Pharmaceuticals NASDAQ: ARNA leading a multidisciplinary research team. Prior to that, Dr. Menzaghi established and directed a preclinical research laboratory at SIBIA Neurosciences, Inc., a biotechnology firm. Her research expertise ranged from the development of small molecules to small peptides. Dr. Menzaghi received her Ph.D. in Neurosciences from the University of Louis Pasteur, Strasbourg, France and a M.Sc. in Clinical Psychology from the University of Nancy, France, after which she conducted her post-doctoral research at the Scripps Research Institute, San Diego, California. Dr. Menzaghi has over 55 peer-reviewed publications and book chapters, 100 international meeting presentations and is listed as an inventor on numerous patents.
- Michael E. Lewis
Michael E. Lewis是我们公司的创始人之一，并在自2004年9月起一直担任公司的首席科技顾问，并在这段期间通过他自己主管的BDP咨询公司向我们提供服务。Lewis博士还曾在2004年9月到2010年7月期间担任我们公司的一名董事。在加入我们之前，Lewis博士联合创立了Arena Pharmaceuticals（纳斯达克：ARNA），并在1997年到2004年期间担任Arena的首席科技顾问，在1997年到2000年期间担任Arena的一名董事；在联合创立Arena之前，Lewis博士还联合创立了Adolor Corporation（纳斯达克：ADLR），并在1994年到1997年期间此担任首席科技顾问；在此之前，Lewis博士还联合创立了Cephalon, Inc.（纳斯达克：CEPH），并自1988年到1989年期间担任高级生物科学技术人员，在1989年到1992年期间担任科学事务的高级主管。Lewis博士获得了 Clark University的心理学博士学位以及关注阿片受体研究的剑桥大学，国家精神健康研究所和密歇根大学的博士后训练。
Michael E. Lewis, Ph.D. Dr. Lewis, one of our founders, has served as our Chief Scientific Advisor since September 2004 during which time he has provided services to us through BioDiligence Partners, Inc., or BDP, a consulting firm controlled by Dr. Lewis. Dr. Lewis also served as a member of our Board of Directors from September 2004 to July 2010. Prior to joining us, Dr. Lewis co-founded Arena Pharmaceuticals NASDAQ: ARNA, and served as Arena’s Chief Scientific Advisor from 1997 to 2004 also serving as a director of Arena from 1997 to 2000. Prior to co-foundingArena, Dr. Lewis co-founded and served as Chief Scientific Advisor of Adolor Corporation (NASDAQ: ADLR) from 1994 to 1997. Prior to that, Dr. Lewis co-founded Cephalon, Inc. (NASDAQ: CEPH), serving as Senior Scientist, Biology from 1988 to 1989 Director of Pharmacology from 1989 to 1992 and Senior Director of Scientific Affairs from 1992 to 1993. Dr. Lewis received a Ph.D. in Psychology from Clark University and post-doctoral training at the University of Cambridge, the National Institutes of Mental Health, and the University of Michigan, with a focus on opioid receptor research. Dr. Lewis is an inventor or co-inventor on 17 issued U.S. patents and is an author or co-author of numerous scientific papers, including over 40 publications on opioids and opioid receptors.- Michael E. Lewis是我们公司的创始人之一，并在自2004年9月起一直担任公司的首席科技顾问，并在这段期间通过他自己主管的BDP咨询公司向我们提供服务。Lewis博士还曾在2004年9月到2010年7月期间担任我们公司的一名董事。在加入我们之前，Lewis博士联合创立了Arena Pharmaceuticals（纳斯达克：ARNA），并在1997年到2004年期间担任Arena的首席科技顾问，在1997年到2000年期间担任Arena的一名董事；在联合创立Arena之前，Lewis博士还联合创立了Adolor Corporation（纳斯达克：ADLR），并在1994年到1997年期间此担任首席科技顾问；在此之前，Lewis博士还联合创立了Cephalon, Inc.（纳斯达克：CEPH），并自1988年到1989年期间担任高级生物科学技术人员，在1989年到1992年期间担任科学事务的高级主管。Lewis博士获得了 Clark University的心理学博士学位以及关注阿片受体研究的剑桥大学，国家精神健康研究所和密歇根大学的博士后训练。
- Michael E. Lewis, Ph.D. Dr. Lewis, one of our founders, has served as our Chief Scientific Advisor since September 2004 during which time he has provided services to us through BioDiligence Partners, Inc., or BDP, a consulting firm controlled by Dr. Lewis. Dr. Lewis also served as a member of our Board of Directors from September 2004 to July 2010. Prior to joining us, Dr. Lewis co-founded Arena Pharmaceuticals NASDAQ: ARNA, and served as Arena’s Chief Scientific Advisor from 1997 to 2004 also serving as a director of Arena from 1997 to 2000. Prior to co-foundingArena, Dr. Lewis co-founded and served as Chief Scientific Advisor of Adolor Corporation (NASDAQ: ADLR) from 1994 to 1997. Prior to that, Dr. Lewis co-founded Cephalon, Inc. (NASDAQ: CEPH), serving as Senior Scientist, Biology from 1988 to 1989 Director of Pharmacology from 1989 to 1992 and Senior Director of Scientific Affairs from 1992 to 1993. Dr. Lewis received a Ph.D. in Psychology from Clark University and post-doctoral training at the University of Cambridge, the National Institutes of Mental Health, and the University of Michigan, with a focus on opioid receptor research. Dr. Lewis is an inventor or co-inventor on 17 issued U.S. patents and is an author or co-author of numerous scientific papers, including over 40 publications on opioids and opioid receptors.